Navigation Links
Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)

Results Set Stage for Development of Sustainable, Organic Livestock and

Fish Feeds

BOCA RATON, Fla., Dec. 4 /PRNewswire-FirstCall/ -- Neptune Industries, Inc. (OTC Bulletin Board: NPDI), a next generation aquaculture technology company with diversified interests in production system technology, food science, sustainable seafood, waste-to-energy production, and related natural and organic food products, announced today that Phase II trials on the Company's Ento-Protein(TM) research has been successfully completed.

The completion of Phase II trials represents the pivotal milestone in developing a viable dietary protein alternative in the $7 billion dollar market for fishmeal. Phase I selected four species of suitable insects based upon a myriad of key production and nutritional parameters. The industry has been focused on vegetable-based alternatives, however these proteins are not well digested by carnivorous fish. Phase II trials proved that fish fed a diet containing Ento-Protein(TM) actually tasted better than those fed fishmeal. The final trial, Phase III, will be used to select the proper blend of insects to achieve the fastest growth rate and optimum digestibility in farm raised fish. The Company anticipates completing the Phase III trial in the first quarter of 2008, constructing its first pilot production facility, and bringing product to market by year end.

The Phase II trials compared juvenile hybrid striped bass fed on a typical fishmeal-based diet, with those fed with Neptune's Ento-Protein(TM), consisting of 100% of the fishmeal portion of their diet. Phase II trial results indicated that the fish fed with Ento-Protein(TM) did not change their behavioral patterns. A panel of sensory experts that evaluated the trials indicated that they favored the fish fed with Ento-Protein(TM) over those fish fed with traditional fishmeal.

Ento-Protein(TM) is a patent-pending high protein fishmeal derived from the controlled, mass production of select insect species, for use in fish and livestock diets. The percentage of fishmeal used in fish feed has declined due to a steady rise in price. According to a key report by Pike and Barlow the market for fish feed is expect to grow from 19.5 million metric tons in 2003 to 37.2 million metric tons in 2010. This market could widen substantially, with the addition of a sustainable, high protein alternative such as Ento- Protein(TM).

Neptune Industries has been involved in a cooperative research relationship with Mississippi State University since January 2007. Phase II trials were a collaborative effort between the Departments of Entomology, Wildlife and Fisheries, and Food Science and Technology.

Dr. Lou D'Abramo, Professor, Department of Wildlife and Fisheries at Mississippi State stated, "In the recent feeding trial, the Ento-Protein(TM) replaced fishmeal as an ingredient of a sustainable diet for hybrid striped bass. No differences in feeding behaviors were found when comparing the control group with the test group. This observation represents an important positive step in realizing the potential for Ento-Protein(TM) in becoming an effective replacement for fishmeal in carnivorous fish diets."

Dr. Patti Coggins, Director, Dept. of Food Science and Technology at Mississippi State commented, "The results of our recent sensory evaluation comparing the taste, texture, aroma, and appearance of the fish on the Ento- Protein(TM) feeding trials were very encouraging. A sensory panel of experts actually favored the flavor of the fish fed with the Ento-Protein(TM) diet over fish on the traditional fishmeal based diets. Also worth mentioning was the break through observation that both the raw and cooked fish had less of a 'fishy' aroma due to the Ento-Protein(TM) feeding. This could be seen as a positive attribute for many potential consumers and positively impact the way alternatives for fish feed are viewed."

President of Neptune Industries, Ernest Papadoyianis, stated, "We believe that our Phase II results set the stage for providing a global solution to the protein shortage that has been plaguing the global aquaculture market. Our research team at Mississippi State University is comprised of some of the most experienced, knowledgeable and recognized individuals in their respective fields. Their unanimous positive feedback to date has further fueled our excitement for the commercialization potential of Ento-Protein(TM). We look forward to commencing our Phase III trials for growth and digestibility very soon."

About Neptune Industries:

Based in Boca Raton, Florida, Neptune Industries, Inc. has developed a scalable, modular aquaculture technology called Aqua-Sphere(TM) and Aqua- Cell(TM) that successfully address the environmental concerns of most aquaculture operations by controlling and recycling all waste products, while insuring the production of the highest quality fish at an affordable price. The company currently operates the Blue Heron Aqua Farms in Florida City, FL and is a leading producer of hybrid striped bass, which it markets internationally as Everglades Striped Bass(TM). The company's current production at its Blue Heron farm, and future production with Aqua-Sphere(TM) System technology are intended to target the organic market as soon as organic certification of farm-raised seafood becomes available. The Company is also in development of an advanced dietary nutritional component called Ento- Protein(TM). Ento-Protein(TM) is a high quality, sustainable protein derived from insects, and is intended to be a replacement for the scarce fishmeal now used in fish and animal diets. For further information, please visit the Company's website at:


Investor Relations Contact:

Michael Steinberg

Chelsea Holdings, Inc.

1200 S. Federal Hwy., Suite 200

Boca Raton, FL 33431



Gary Geraci

Equity Performance Group



Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

SOURCE Neptune Industries
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Linden Care, LLC, a retail ... outcomes for patients suffering from chronic pain, said today ... Temporary Restraining Order (TRO) enjoining Express Scripts from unilaterally ... --> --> The ... its legal options. --> ...
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... , Nov. 25, 2015  Henry Schein, Inc., the ... to office-based dental, medical and animal health practitioners, will ... the Henry Schein ConnectDental® Pavilion , which brings ... of open solutions designed to help any practice or ... here for a schedule of experts appearing at ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today that ... (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ERP ... partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the first ... annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the International ... November 11th, 2015. The conference was held at the Hawaii Convention Center in ...
Breaking Medicine News(10 mins):